Blood Clotting Activities of Thrombolytic Agents with Special Reference to a Hageman-like Effect^[*]

Summary

Representatives of modern thrombolytic agents have been shown to possess certain in vitro clot accelerating activities, which a variety of experiments indicate to be due to a ^‘Hageman-like^’ effect. This activity is surface dependent and remarkably resistant to long keeping (in active plasmin) and to acid heating, unlike ‘surface factor^’ (‘activation product^’). The effect is quite powerful under certain test conditions, but it remains to be seen whether it is of any significance during the use of thrombolytic agents therapeutically.

^* Aided by a grant (H 1510—C₇) from the N.I.H. Division of Research Grants and Fellowships, U. S. P. H. S.

^** Appointment supported by the International Cooperation Administration, under the Visiting Research Scientists Program administered by the National Academy of Sciences of the United States of America.

• References

• 1 Nolf P. The coagulation of the blood. Medicine 17: 381 1938;
• 2 Ferguson J. H. Lipoids and blood platelets, with reference to blood coagulation and the hemorrhagic diseases. Univ. N. Carolina Press; 278 1960
• 3 Ferguson J. H, Wilson E. G, Iatridis S. G, Rierson H. A, Johnston B. R. Enzymes and blood clotting. I. Trypsin as an accessory factor. J. clin. Invest., submitted. 1960
• 4 Milstone J. H. TAMe esterase activity of blood thrombokinase after repeated electrophoretic fractionations. Proc. Soc. exp. Biol. Med. 103: 361 1960;
• 5 Ferguson J. H. A new blood-clotting theory. Science 97: 319 1943;
• 6 Ratnoff O. D, Hartmann R. C, Conley R. L. Studies on a proteolytic enzyme in human plasma. V. The relationship between the proteolytic activity of plasma and blood coagulation. J. exp. Med. 91: 123 1950;
• 7 Ratnoff O. D, Colopy J. E. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J. clin. Invest. 34: 602 1955;
• 8 Sherry S, Fletcher A. P, Alkjaersig N. Fibrinolysis and fibrinolytic activity in man. Physiol. Rev. 39: 343 1959;
• 9 Müllertz S. Formation and properties of the activator of plasminogen and of human bovine plasmin. Biochem. J. 61: 424 1955;
• 10 Loomis E. C, George Jr. C, Ryder A. Fibrinolysin, nomenclature, unit, assay, preparation and properties. Arch. Biochem. 12: 1 1947;
• 11 Johnston Jr. C. L, Ferguson J. H, O’Hanlon F. A. Surface activation of plasma clotting: a function of Hageman factor. Proc. Soc. exp. Biol. Med. 99: 197 1958;
• 12 Lewis J. H, Ferguson J. H, Fresh J. W, Zucker M. B. Primary hemorrhagic diseases. J. Lab. clin. Med. 49: 211 1957;
• 13 Quick A. J, Stanley-Brown M, Bancroft F. W. A study of the coagulation defect in hemophilia and in jaundice. Amer. J. med. Sci. 190: 501 1935;
• 14 Langdell R. D, Wagner R. H, Brinkhous K. M. Effect of antihemophilic factor on one-stage clotting tests. A presumptive test for hemophilia and a simple one-stage antihemophilic factor assay procedure. J. Lab. clin. Med. 41: 637 1953;
• 15 Owren P. A. Prothrombin and accessory factors. Amer. J. Med. 14: 201 1953;
• 16 Hardisty R. M, Margolis J. The role of Hageman factor in the initiation of blood coagulation. Brit. J. Haematol. 05: 203 1959;
• 17 Waaler B. A. Contact activation in the intrinsic blood clotting system. Scand. J. clin. Invest. 11 Suppl. 135 1959;
• 18 Soulier J. P, Larrieu M. J. Deficit en 3ème facteur prothromboplastique plasmatique. Rapports entre le PTA et le facteur Hageman. Thromb. Diath. haem. 02: 2 1958;
• 19 Margolis J. The role of Hageman factor in plasma/surface reactions. In ‘Hemophilia and other hemorrhagic states’, Internat. Sympos., Rome, ed. Brinkhous K. M, de Nicola P. Univ. N. Carolina Press; 208 1959
• 20 Richard M. N, Cole R. B, Smith W. E, Baumgarten W. Analytical evaluation of plasminogen purification. Vox sang. 04: 126 1959;